02 August 2022 : Original article
The Association Between Tacrolimus Levels and Hyperkalemia in Allograft Recipients Who Underwent Heart or Lung Transplantation in New Orleans, USA Between 2013 and 2019: A Single-Center Retrospective Study
Olivia L. Griffis
1ABCDEF*, Steven Q. Thai1ABCDEF, Cody Allison1ABCDEF, Brooke Baetz1ABCDEF, Alaa Mohammed23CE
DOI: 10.12659/AOT.935607
Ann Transplant 2022; 27:e935607
Table 1 Baseline characteristics off tacrolimus (pre-transplant) vs on tacrolimus (30-days post-transplant).
| Total cohort (N=103) | Off tacrolimus | On tacrolimus | P value | |
|---|---|---|---|---|
| Age, years | 58.0 (40.0–61.0) | ---- | ---- | ---- |
| Female | 42 (40.8%) | ---- | ---- | ---- |
| African American | 14 (13.6%) | ---- | ---- | ---- |
| eGFR, mL/min/1.73 m | ---- | 89.7 (73.7–110.7) | 68.8 (48.6–87.4) | <0.0001 |
| Tacrolimus level, ng/mL | ---- | ---- | 11.0 (8.1–13.5) | ---- |
| Blood glucose level, mg/dL | ---- | 101.0 (89.0–124.0) | 108.0 (93.0–131.0) | 0.028 |
| ACE/ARB | ---- | 24 (23.3%) | 6 (5.8%) | <0.0001 |
| Spironolactone/eplerenone | ---- | 0 (0%) | 0 (0%) | ---- |
| SMX/TMP | ---- | 5 (4.9%) | 93 (90.3%) | <0.0001 |
| Insulin | ---- | 19 (18.5%) | 37 (35.9%) | 0.0001 |
| Loop/thiazide diuretic | ---- | 0 (0%) | 20 (19.4%) | ---- |
| Non-selective beta blocker | ---- | 0 (0%) | 2 (1.9%) | ---- |
| Potassium binder | ---- | 0 (0%) | 7 (6.8%) | ---- |
| Potassium supplementation | ---- | 0 (0%) | 0 (0%) | ---- |
| Posaconazole/itraconazole | ---- | 0 (0%) | 20 (19.4%) | ---- |
| ACE – angiotensin-converting enzyme inhibitors; ARB – angiotensin II receptor blockers; eGFR – estimated glomerular filtration rate; SMX/TMP – sulfamethoxazole/trimethoprim. ‘----’ – no statistical analysis available. All categorical values are represented by a number followed by the percentage in parentheses. All continuous values are represented by a median followed by the interquartile range in parentheses. | ||||